ARTICLE | Clinical News
Genasense G3139: Started Phase III trial
February 20, 2001 8:00 AM UTC
Genta Inc. (GNTA), Berkeley Heights, N.J. Product: Genasense G3139 Business: Cancer Therapeutic category: Apoptosis, Antisense Target: Bcl-2 protein Description: Antisense agent targeting Bcl-2 to in...